<DOC>
	<DOCNO>NCT00078975</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 3-AP gemcitabine , work different way stop tumor cell divide stop grow die . 3-AP may help gemcitabine kill tumor cell make sensitive drug . PURPOSE : This phase II trial study well give 3-AP together gemcitabine work treat patient recurrent , unresectable , metastatic pancreatic cancer .</brief_summary>
	<brief_title>3-AP Gemcitabine Treating Patients With Recurrent , Unresectable , Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity 3-AP ( Triapine® ) gemcitabine , term complete partial response 6-month progression-free disease , patient recurrent , unresectable , metastatic pancreatic cancer . Secondary - Determine objective response rate , median survival , 1-year survival rate , duration response stable disease , progression-free survival patient treat regimen . - Determine safety tolerability regimen patient . OUTLINE : This multicenter study . Patients receive 3-AP ( Triapine® ) IV 2 hour gemcitabine IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients achieve complete partial response receive additional 2 course therapy beyond response . Patients follow every 3 month . PROJECTED ACCRUAL : A total 28-50 patient accrue study within 7-13 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma Recurrent , unresectable , metastatic disease At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan Prior radiation field must encompass site measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 12 week Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No G6PD deficiency Hepatic Bilirubin ≤ 1.5 time normal AST ALT ≤ 2.5 time upper limit normal Renal Creatinine ≤ 1.5 time normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No unstable angina pectoris No cardiac arrhythmia No symptomatic congestive heart failure Pulmonary No severe pulmonary disease No dyspnea rest No dependence supplemental oxygen use Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study treatment No prior allergic reaction attribute compound similar chemical biological composition study drug No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy except fluorouracil give adjuvant therapy OR radiosensitizer radiotherapy More 4 week since prior adjuvant fluorouracil therapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics See Chemotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other No concurrent investigational agent No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>